Patents Assigned to GlaxoSmithKline LLC
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20150126522
    Abstract: This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 7, 2015
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Celine Duquenne, Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • Benzodiazepine bromodomain inhibitor
    Patent number: 9023842
    Abstract: The present invention relates to a benzodiazepine compound of formula (I), processes for its preparation, pharmaceutical compositions containing such a compound and to its use in therapy.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: May 5, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Romain Luc Marie Gosmini, Olivier Mirguet
  • Indazoles
    Patent number: 9018382
    Abstract: Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 28, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Celine Duquenne, Neil Johnson, Steven D. Knight, Louis LaFrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Pyrazolylaminopyridines as inhibitors of FAK
    Patent number: 9012479
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R11, R12, R13, Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: April 21, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry Leroy Adams, Thomas H. Faitg, Neil W. Johnson, Hong Lin, Xin Peng
  • COMBINATION
    Publication number: 20150094321
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
    Type: Application
    Filed: May 6, 2014
    Publication date: April 2, 2015
    Applicant: GlaxoSmithKline LLC
    Inventors: Melissa DUMBLE, Tona Gilmer, Rakesh Kumar, Peter F. Lebowitz, Shannon Renae Morris, Sylvie LaQuerre
  • Tetrahydroquinoline derivatives useful as bromodomain inhibitors
    Patent number: 8993554
    Abstract: Tetrahydroquinoline compounds, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: March 31, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Dominique Amans, Emmanuel Hubert Demont, Darren Jason Mitchell, Jonathan Thomas Seal
  • Vapor sheath for liquid dispensing nozzle
    Patent number: 8986777
    Abstract: The present disclosure provides a device for preventing the fouling of a liquid dispensing nozzle. The end of the dispensing nozzle is placed in a hollow interior of a band carrying the same solvents that are dispensed by the nozzle. The solvent on the band evaporates into a gap between the ring and dispensing nozzle, thus providing a vapor sheath or environment that helps to prevent the fouling of the dispensing nozzle.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: March 24, 2015
    Assignee: GlaxoSmithKline, LLC
    Inventors: Allan J. Clarke, Frederick H. Fiesser, James A. McHugh
  • 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID bis-(MONOETHANOLAMINE)
    Publication number: 20150079030
    Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 19, 2015
    Applicant: GlaxoSmithKline LLC
    Inventor: Stephen Moore
  • Calcilytic compounds
    Patent number: 8980950
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 17, 2015
    Assignee: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Indoles
    Patent number: 8975291
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: March 10, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: James Brackley, III, Joelle Lorraine Burgess, Seth Grant, Neil Johnson, Steven D. Knight, Louis Lafrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Vapor sheath for liquid dispensing nozzle
    Patent number: 8967074
    Abstract: The present disclosure provides a device for preventing the fouling of a liquid dispensing nozzle. The end of the dispensing nozzle is placed In a hollow interior of a band carrying the same solvents that are dispensed by the nozzle. The solvent on the band evaporates into a gap between the ring and the dispensing nozzle, thus providing a vapor sheath or environment that helps to prevent the fouling of the dispensing nozzle.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: March 3, 2015
    Assignee: GlaxoSmithKline, LLC
    Inventors: Allan J. Clarke, Frederick H. Fiesser, James A. McHugh
  • Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
    Patent number: 8952018
    Abstract: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: February 10, 2015
    Assignee: GlaxosmithKline LLC
    Inventors: Melissa Dumble, Rakesh Kumar, Sylvie Laquerre, Peter Lebowitz
  • Inhibitors of AkT activity
    Patent number: 8946278
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McNulty
  • Nicotine lozenge composition
    Patent number: 8940772
    Abstract: The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: January 27, 2015
    Assignee: GlaxoSmithKline, LLC
    Inventor: Li-Lan Chen
  • Medical product dispensing systems and methods
    Patent number: 8930207
    Abstract: Methods and systems for transferring restricted distribution medical products to an over-the-counter general sales environment are provided. Methods and systems of dispensing non-prescription, behind-the-counter medical products from a vending machine in a general sales location are also provided. In some embodiments, methods and systems are provided for dispensing a medical product from a vending machine in a general sales location based, at least in part, on biometric data collected from the purchaser and, in some instances, based on self-selection and/or de-selection criteria, is provided. Further, methods and systems of switching prescription medical products to non-prescription, over-the-counter medical products are provided.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Daniel Paul Keravich, Richard Alexander McGregor, George Michael Quesnelle
  • Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
    Patent number: 8912205
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: December 16, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey
  • Imidazopyridine derivatives as PI3 kinase
    Patent number: 8906910
    Abstract: This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective imidizopyridine compounds for treating cancer.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: December 9, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Ralph A. Rivero, Rosanna Tedesco
  • AZAINDAZOLES
    Publication number: 20140343056
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: September 12, 2012
    Publication date: November 20, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
  • Chemica compounds
    Patent number: 8889726
    Abstract: Disclosed are compounds of Formula I, Formula II, and Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Subramanian Baskaran, Richard Martin Grimes, Wieslaw Mieczyslaw Kazmierski, Martin Robert Leivers
  • Continuous coating of pellets
    Patent number: 8887659
    Abstract: A continuous dosage form coating apparatus uses vibrational impulses to maintain a dosage forms in a fluid state to expose them to a coating material atomized by spraying.
    Type: Grant
    Filed: February 18, 2008
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline LLC
    Inventor: Frederick H. Fiesser